Icrucumab ELISA Kit (DB265018)

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	DB265018
Description	Icrucumab ELISA Kit (DB265018) — Quantitative sandwich ELISA for Icrucumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Sample type	Plasma, Serum
Sensitivity	0.156 μg/ml
Range	0.31-5 μg/mL
Accession	P17948
Applications	ELISA
Detection method	Colorimetric
Assay type	Quantitative
Recovery	80-120%
Shipping	2-8 ℃
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Specifications	Icrucumab
Alternate Names	18F1, IMC-18F1, LY3012212, 1024603-92-6
Background	Vascular endothelial growth factor receptor 1 (Icrucumab) is a ~150 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. 1. Lesslie, DP. et al. (2006) British journal of cancer 94, 1710-7. PMID: 16685275
Note	For Research Use Only.